Many gained access to GLP-1s through Medicaid’s decision in late 2024 to cover these weight loss drugs. But these medications remain out of reach for millions of patients across the US.
Updated labeling highlights the potential risks of pulmonary aspiration associated with popular GLP-1 medications during procedures requiring deep sedation or general anesthesia